EXHIBIT 99.2
SUPPLY AND SERVICES AGREEMENT
This Supply and Services Agreement (this "AGREEMENT") is
entered into as of August 29, 2001, by and between SeraCare, Inc., a Delaware
corporation ("SERACARE"), and SeraCare Life Sciences, Inc., a California
corporation and wholly-owned subsidiary of SeraCare ("LIFE SCIENCES"). SeraCare
and Life Sciences are sometimes referred to herein individually as a "PARTY" or
collectively as the "PARTIES."
RECITALS
WHEREAS, SeraCare has entered into an Agreement and Plan of
Merger (the "MERGER AGREEMENT") with Instituto Grifols, S.A., a company
organized under the laws of Spain ("GRIFOLS"), pursuant to which SeraCare will
merge with and into SI Merger Corp., a Delaware corporation and wholly-owned
subsidiary of Grifols (the "MERGER"), provided that all of the conditions
precedent to the Merger set forth in the Merger Agreement have been satisfied;
WHEREAS, the parties have determined that it is appropriate
and desirable to distribute to the holders of SeraCare's common stock, by means
of a pro rata distribution immediately prior to the effective time of the
Merger, all of the shares of Life Sciences common stock (the "DISTRIBUTION");
WHEREAS, the parties desire to set forth herein terms and
conditions pursuant to which SeraCare agrees to supply, and Life Sciences agrees
to purchase and accept, certain plasma products, and SeraCare agrees to perform
certain plasmapheresis services on referred donors, and Life Sciences agrees to
purchase and accept such referred donor plasma, following the Distribution.
NOW, THEREFORE, in consideration of the foregoing and the
mutual covenants and agreements set forth below, the parties, intending to be
legally bound, hereby agree as follows:
1. PRODUCTS, SERVICES PRICES AND PAYMENT
1.1 Life Sciences agrees to purchase from SeraCare, and
SeraCare agrees to sell to Life Sciences, plasma-related products (the
"PRODUCTS") set forth on EXHIBIT A attached hereto at such prices as set forth
on Exhibit A. Life Sciences and SeraCare represent and warrant that such prices
were determined as a result of arms-length negotiation between the parties. The
parties shall negotiate annually in good faith mutually acceptable price
adjustments (increase or decrease) of the Products based on factors the parties
deem relevant including the then prevailing market price for such products,
regulatory issues and testing requirements. Such price adjustment shall be
effective upon each anniversary of the initial, or any renewal term, of this
Agreement, provided that in the event that there are changes in any legal or
regulatory requirements that materially impact SeraCare's costs of the Product
production, the parties shall, prior to such annual negotiations, negotiate in
good faith price increases or decreases not to exceed the direct costs of such
change in legal or regulatory requirements, provided further that in no event
shall the price for the Products exceed the fair market value for the Products.
If the
1
parties are unable to reach agreement on an annual price adjustment as provided
for herein, then the parties shall submit the matter to dispute resolution as
provided for in Section 8.5.
1.2 Subject to Life Sciences' Standard Operating Procedures
and any applicable requirements relating to a subject donor's medical condition,
SeraCare agrees it shall (i) perform automated plasmapheresis bleedings on all
donors referred by Life Sciences (the "PLASMAPHERESIS SERVICES"), and that Life
Sciences shall have the right to receive all blood plasma collected by SeraCare
which is derived from such referred donors (the "REFERRED DONOR PLASMA"), and
(ii) if and when SeraCare acquires an appropriately licensed and equipped
center, draw blood on all donors referred by Life Sciences (the "BLOOD DRAWING
SERVICES"), and that Life Sciences shall have the right to receive all whole
blood, off the clot, serum, et. al. therefrom (the "REFERRED DONOR BLOOD,"
collectively, with the Referred Donor Plasma, the "REFERRED DONOR PRODUCTS.")
SeraCare shall conduct viral marker testing and FDA required confirmatory
testing on all Referred Donor Products (the "TESTING SERVICES"). The price,
including softgoods, (but excluding donor fees which shall be payable by Life
Sciences) for such Plasmapheresis Services, Blood Drawing Services, Testing
Services and Referred Donor Products (collectively, the "REFERRED DONOR
SERVICES") shall be as set forth on Exhibit A , as amended from time to time in
accordance with this Agreement. Life Sciences and SeraCare represent and warrant
that such prices were determined as a result of arms-length negotiation between
the parties. The parties shall negotiate annually in good faith mutually
acceptable price adjustments (increase or decrease) of the Referred Donor
Services based on factors the parties deem relevant including the then
prevailing market price for such products, regulatory issues and testing
requirements. Such price adjustment shall be effective upon each anniversary
date of the initial, or any renewal term, of this Agreement, provided that in
the event that there are changes in any legal or regulatory requirements that
materially impact SeraCare's costs of the Referred Donor Services, the parties
shall, prior to such annual negotiations, negotiate in good faith price
increases or decreases not to exceed the direct costs of such change in legal or
regulatory requirements, provided further that in no event shall the price for
the Referred Donor Services exceed the fair market value for the Referred Donor
Services. If the parties are unable to reach agreement on an annual price
adjustment as provided for herein, then the parties shall submit the matter to
dispute resolution as provided for in Section 8.5.
1.3 Payment by Life Sciences for any Products will be made
within thirty (30) days from date of delivery of such Products by SeraCare, and
payment by Life Sciences for any Referred Donor Services will be made within
thirty (30) days from the date of delivery of the Referred Donor Products by
SeraCare.
1.4 All costs of shipment, freight, insurance and all
government taxes and duties incurred in connection with shipment of the Products
and the Referred Donor Products to Life Sciences or Life Sciences customers will
be paid by Life Sciences.
1.5 Life Sciences agrees that it shall exclusively use the
appropriately licensed Centers (as hereinafter defined) for donors in respect of
Referred Donor Services for all donors who reside within reasonable proximity to
an appropriately licensed Center.
2. DELIVERY, STORAGE AND HANDLING
2
2.1 All Products and Referred Donor Products will be packed
and shipped in accordance with SeraCare's established Standard Operating
Procedures that significantly relate to the collection of blood plasma in effect
as of the date hereof, as may be amended from time to time as provided for in
Section 3.1, and all applicable sections of the Code of Federal Regulations,
including all applicable sections and regulations issued or promulgated by the
United States Food and Drug Administration, as well as any other applicable
federal, state, and local regulations concerning the collection, packaging,
processing, storing or shipping of the Products. All shipments of the Products
and Referred Donor Products will contain all duly and properly prepared
documentation required by applicable laws or regulations.
2.2 Life Sciences shall deliver to SeraCare a purchase order
with the specifications of each order of the Products.
2.3 Title and all risk of loss and damage regarding the
Products and the Referred Donor Products shall pass to Life Sciences upon
delivery to Life Sciences, except for Products or Referred Donor Products
rejected pursuant to Section 3.3.
2.4 Life Sciences agrees that upon delivery of Products and
Referred Donor Products to Life Sciences, Life Sciences shall handle, store and
maintain all Products and Referred Donor Products in an appropriate environment
in accordance with applicable law, industry standards and good manufacturing
practices. If Life Sciences shall fail to handle, store and maintain any
Products or Referred Donor Products in accordance with this Agreement, such
Products or Referred Donor Products shall not be subject to rejection as
provided below. Life Sciences shall indemnify SeraCare pursuant to Section 8.1
hereof in the event that any third-party claims arise because of any failure by
Life Sciences to handle, store and maintain Products or Referred Donor Products
in accordance with this Agreement.
3. PRODUCT QUALITY AND USE
3.1 All Products sold to Life Sciences hereunder shall conform
to the quality and technical specifications set forth for such Products on
EXHIBIT B attached hereto (the "MINIMUM SPECIFICATIONS"), provided that SeraCare
may modify its Standard Operating Procedures (which are included in the Minimum
Specifications) only if such modification (i) relates solely to a change
required by law (based on the advice of nationally recognized healthcare
regulatory counsel) and SeraCare notifies Life Sciences of such modification at
least five business days prior to the effective date of such modification, (ii)
does not significantly relate to the collection of blood plasma, or (iii) is not
required by law (based on the advice of nationally recognized healthcare
regulatory counsel) and SeraCare has obtained written consent of such change
from Life Sciences. In addition, SeraCare agrees that the Products delivered to
Life Sciences shall not be misbranded or adulterated within the meaning of the
Federal Food, Drug and Cosmetic Act, and shall be in full compliance with the
Biological Products Section of the Public Health Service Act, and applicable
regulations, and shall be in full compliance with any applicable international,
federal, state or local laws, ordinances or regulations in accordance with past
practice. Subject to Section 8.14 hereof, in the event SeraCare ships to Life
Sciences any Products which are not in compliance with such laws, regulations or
the Minimum Specifications, then SeraCare will be liable to Life Sciences for
damages arising out of relating
3
to such non-compliant Products (including, without limitation, attorneys fees,
arbitrators' fees, costs of experts and court costs).
3.2 All Referred Donor Services performed hereunder shall
conform to the quality and technical specifications set forth for such Referred
Donor Services on EXHIBIT C attached hereto (the "REFERRED DONOR MINIMUM
SPECIFICATIONS"), provided that Life Sciences may modify the Minimum
Specifications upon written notification to SeraCare with such modifications to
be effective within five (5) business days of delivery of such notification. In
addition, SeraCare agrees that the Referred Donor Products delivered to Life
Sciences shall not be misbranded or adulterated within the meaning of the
Federal Food, Drug and Cosmetic Act, and shall be in full compliance with the
Biological Products Section of the Public Health Service Act, and applicable
regulations, and shall be in full compliance with any applicable international,
federal, state or local laws, ordinances or regulations in accordance with past
practice. Subject to Section 8.14 hereof, in the event SeraCare ships to Life
Sciences any Referred Donor Products which is not in compliance with such laws,
regulations or the Referred Donor Minimum Specifications, then SeraCare will be
liable to Life Sciences for damages arising out of relating to such
non-compliant Referred Donor Products (including, without limitation, attorneys
fees, arbitrators' fees, costs of experts and court costs).
3.3
(A) All Referred Donor Products furnished by SeraCare to Life
Sciences hereunder which does not meet the Referred Donor Minimum
Specifications, and all Products furnished by SeraCare to Life Sciences
hereunder which do not meet the Minimum Specifications, or which are, in Life
Sciences' reasonable judgment, otherwise defective shall be subject to rejection
notwithstanding prior payment by Life Sciences, provided that any rejection of
Referred Donor Products or Products, other than de minimis rejections, shall be
accompanied by a written explanation from Life Sciences setting forth the basis
or bases for such rejection. SeraCare acknowledges and agrees that Life Sciences
may reject any Products that do not conform to the Minimum Specifications, or
any Referred Donor Products that does not conform to the Referred Donor Minimum
Specifications, at any time up to thirty (30) business days after delivery of
such Products or Referred Donor Products to Life Sciences or Life Sciences
customers, provided that any Products or Referred Donor Products not rejected
during such period shall be deemed to be accepted by Life Sciences.
(B) Subject to Section 2.4 and 8.14 hereof, Life Sciences
shall have no liability whatsoever with respect to such rejected Products or
Referred Donor Products and SeraCare shall reimburse Life Sciences for any and
all costs and expenses (including but not limited to shipment, freight,
insurance and all government taxes and duties incurred during shipment,
transportation, storage, handling and pooling costs) which are incurred by Life
Sciences with respect to any such rejected Products or Referred Donor Products.
SeraCare shall have the right to instruct Life Sciences to (i) return any
rejected Products or Referred Donor Products to SeraCare (after receiving
notification of such rejection) or (ii) destroy such rejected Products or
Referred Donor Products in lieu of returning them to SeraCare, provided that
Life Sciences shall use its best efforts to dispose of such rejected Products or
Referred Donor Products in accordance with all applicable law and regulations.
In the event SeraCare does not give instructions regarding the disposition of
such rejected Products or Referred Donor Products
4
within fifteen (15) business days after notice of rejection of the Products
or Referred Donor Products by Life Sciences to SeraCare, Life Sciences shall
have the right to destroy or otherwise dispose of all such rejected Products
or Referred Donor Products at SeraCare's sole expense without any liability
whatsoever to SeraCare and without obligation to compensate SeraCare for any
part of such rejected Products or Referred Donor Products.
3.4 Subject to the terms and conditions contained herein,
including without limitation the liability limitation in Section 8.14, in the
event Life Sciences makes prior payment for Products or Referred Donor Products
which are later rejected in accordance with this Agreement, the purchase price
of such rejected Products or Referred Donor Products, and any other costs and
expenses incurred by Life Sciences in connection with such rejected Products or
Referred Donor Products, may be set off or deducted from any other payments due
to SeraCare from Life Sciences. In addition, Life Sciences shall have the right,
at its sole election, to demand reimbursement, in cash, for the purchase price
and any other sums paid in connection with any such rejected Products or
Referred Donor Services, subject to SeraCare's right to set off or deduct
payments due from Life Sciences.
3.5 Life Sciences represents and warrants to SeraCare that the
Products and the Referred Donor Products shall be manufactured and distributed
solely for diagnostic purposes and not for human consumption or otherwise for
injection into humans.
4. REGULATORY REQUIREMENTS
4.1 SeraCare represents and warrants that as of the date of
this Agreement, each of the centers set forth on EXHIBIT D attached hereto, as
amended from time to time in accordance herewith, (the "Centers" or individually
a "Center") is Licensed as hereinafter defined. For purposes of this Agreement,
a Center is Licensed when it has (i) a license issued by the United States Food
and Drug Administration (the "FDA"); (ii) is Quality Plasma Program ("QPP")
certified, and (iii) has all other material permits and licenses which are
required by federal, state or local regulatory agencies in order for SeraCare to
operate the Centers, except for the Centers located in Danville, Virginia and
Providence, Rhode Island, for which SeraCare agrees to use its best efforts to
obtain QPP certification. SeraCare agrees that all of the Products sold by
SeraCare to Life Sciences hereunder will be collected only at the Centers, and
all of the Referred Donor Services will be performed only at the Centers.
SeraCare shall immediately notify Life Sciences if any Center is no longer
Licensed, and the parties expressly agree that any Center that is no longer
Licensed will be deleted from Exhibit D.
4.2 SeraCare agrees that it shall operate the Centers in
material compliance with applicable federal, state and local laws, rules and
regulations. SeraCare also agrees to be solely responsible for ensuring that its
Centers materially comply with laws, rules and regulations pertaining to
occupational safety and health, blood borne pathogens and good manufacturing
practices.
4.3 If at any time during the term of this Agreement SeraCare
receives written notice (a "Compliance Notice") from any federal, state or local
governmental entity or agency that any Center is out of compliance in any
material respect with applicable federal, state or local laws, rules or
regulations, SeraCare agrees that it will inform Life Sciences within five (5)
5
business days of its receipt of such written notification. For purposes hereof,
a FDA Form 483 notice or similar inspection report shall be deemed to be a
Compliance Notice. Within thirty (30) days after notifying Life Sciences of such
non-compliance, SeraCare shall deliver written notice informing Life Sciences of
its election either to (i) remove the non-compliant Center from Exhibit D, or
(ii) provide Life Sciences with a written proposal in which SeraCare sets forth
the commercially reasonable efforts that it will use to, and projected timetable
within which it will, bring the non-compliant Center into material compliance.
If SeraCare elects to try to bring a non-compliant Center into material
compliance and satisfies the concerns of the subject governmental entity or
agency enumerated in the Compliance Notice, or, six months after responding to
such Compliance Notice, SeraCare has received no further correspondence from the
subject governmental entity in respect thereof, the Center which is the subject
of such Compliance Notice shall be deemed to be in compliance with this
Agreement and shall not be removed from Exhibit D. If SeraCare elects to try to
bring a non-compliant Center in to material compliance but is unsuccessful, in
the reasonable determination of Life Sciences, in bringing such center into
material compliance herewith and with such Compliance Notice within thirty (30)
days of the date of delivery of the written proposal referred to in clause (ii)
of this Section 4.3, either party notify the other that it elects to remove the
non-compliant Center from Exhibit D, and that Center's removal will be effective
immediately upon delivery of that notice.
4.4 The parties further agree that Life Sciences has the right
to inspect any Center on 24 hours' notice and at Life Sciences' sole expense
during normal business hours to ensure material compliance with applicable
regulations. Life Sciences agrees to conduct such inspection in a reasonable
manner. If SeraCare receives from Life Sciences a notice of non-compliance
resulting from the inspection, within thirty (30) days of receipt of such notice
of such non-compliance, SeraCare shall deliver written notice informing Life
Sciences of its election either to (i) remove the non-compliant Center from
Exhibit D, or (ii) provide Life Sciences with a written proposal in which
SeraCare sets forth the commercially reasonable efforts that it will use to, and
projected timetable within which it will, bring the non-compliant Center into
material compliance. If SeraCare elects to try to bring a non-compliant Center
in to material compliance, and the relevant remediation efforts cause the Center
to be able to produce Products or collect Referral Donor Products in accordance
with the Minimum Specifications, or Referred Donor Minimum Specifications, as
the case may be, and the Center is otherwise in compliance with all applicable
laws and regulations, the Center which is the subject of the non-compliance
shall be deemed to be in compliance with this Agreement and shall not be removed
from Exhibit D. If SeraCare elects to try to bring a non-compliant Center into
material compliance but is unsuccessful, in the reasonable determination of Life
Sciences, within thirty (30) days from the date of delivery of the written
proposal referred to in clause (ii) of this Section 4.4, either party notify the
other that it elects to remove the non-compliant Center from Exhibit D, and that
Center's removal will be effective immediately upon delivery of that notice.
5. ACCESS TO DONOR BASE
Subject to applicable laws and regulations regarding the
confidentiality of donor information, SeraCare agrees that it shall grant Life
Sciences continuing access during the term of this Agreement to its donor base
of all donors who signed a consent form to allow donor history to be included in
the database, (the "consented donor base") including donor history files. The
parties acknowledge that as of the date of this Agreement to their knowledge and
after
6
reasonable investigation HIPAA does not apply to SeraCare and the donor
information provided to Life Sciences pursuant to this Agreement. SeraCare shall
provide Life Sciences such information in a reasonable format requested by Life
Sciences within a reasonable time period, which in no event shall exceed five
(5) business days from the date of the request.
6. WARRANT
Immediately following the Distribution, Life Sciences shall
grant Instituto Grifols, S.A., or its affiliate, a warrant, in accordance with
the terms of the Warrant Agreement attached hereto as EXHIBIT E, to purchase up
to ten (10) percent of the outstanding common stock of Life Sciences immediately
following the Distribution, which, for purposes of example, if calculated as of
the date hereof (assuming conversion of the warrants issued to by SeraCare to
Nap & Co., Fuelship & Co., Northman & Co., and Hare & Co.) would be 1,388,962
shares of common stock of Life Sciences.
7. TERM AND TERMINATION
7.1 TERM. The term of this Agreement shall commence
immediately following the Distribution and shall continue until January 24,
2006, unless earlier terminated or extended as provided herein. This Agreement
shall automatically terminate and be of no further force and effect in the event
the Merger Agreement is terminated.
7.2 TERMINATION.
(A) Upon the occurrence of any of the following events, Life
Sciences shall be entitled to (a) receive immediate written notice of the
occurrence of such event and (b) terminate this Agreement immediately by giving
written notice of termination to SeraCare:
(1) In the event of insolvency of SeraCare or in the event
that in involuntary or voluntary petition in bankruptcy is filed by, against or
on behalf of SeraCare;
(2) In the event SeraCare makes a general assignment for
the benefit of its creditors, or a receiver or trustee is appointed for its
business or property;
(3) In the event three (3) or more Centers materially fail
any inspection by Life Sciences, the FDA or any applicable federal, state or
local government agency in any twelve month period, and the circumstances giving
rise to such inspection is not cured as contemplated by Section 4; or
(4) In the event SeraCare fails to observe the terms of
this Agreement and such failure shall continue to exist for thirty days after
written notice of such failure has been given to SeraCare.
(B) Upon the occurrence of any of the following events,
SeraCare shall be entitled to (a) receive immediate written notice of the
occurrence of such event and (b) terminate this Agreement immediately by giving
written notice of termination to Life Sciences:
7
(1) In the event of insolvency of Life Sciences or in the
event that in involuntary or voluntary petition in bankruptcy is filed by,
against or on behalf of Life Sciences;
(2) In the event Life Sciences makes a general assignment
for the benefit of its creditors, or a receiver or trustee is appointed for its
business or property; or
(3) In the event Life Sciences fails to observe the terms
of this Agreement and such failure shall continue to exist for thirty days after
written notice of such failure has been given to Life Sciences.
(C) Failure or delay by either party in terminating this
Agreement following the occurrence of any event specified in Section 8.2 (A) or
(B) above or following any other breach of this Agreement shall not constitute a
waiver of such party's right to terminate this Agreement.
(D) Subject to Section 8.14 hereof, no termination of this
Agreement shall release or discharge either of the parties from any debt or
liability which shall have been incurred or accrued prior to the date of
termination.
7.3 RENEWAL. The first or any subsequent term of this
Agreement shall automatically be extended for successive renewal terms of one
year each in duration, on the otherwise same terms and conditions, unless either
party provides written notice of intent not to extend to the other party on or
at anytime before four months prior to the expiration of the then current term.
8. MISCELLANEOUS
8.1 INDEMNIFICATION. Subject to Section 8.14, each party
hereto (the "Indemnifying Party") shall, to the extent of the Indemnifying
Party's proportionate share of fault, if any, indemnify and hold harmless the
other party and its officers, directors, employees, agents, representatives,
contractors and subcontractors from and against any and all claims or causes of
action brought by any third party or third parties arising out of any act or
omission of the Indemnifying Party in connection with this Agreement.
8.2 INSURANCE. SeraCare agrees to carry at its sole cost and
expense during the term of this Agreement and for a reasonable time thereafter,
product and professional liability insurance consistent with prudent business
practices in the industry with respect to the Products and Referred Donor
Services in an amount not less than $300,000 per occurrence for product
liability and not less than $500,000 per occurrence for professional liability.
Life Sciences agrees to carry at its sole cost and expense during the term of
this Agreement and for a reasonable time thereafter, product insurance
consistent with prudent business practices in the industry for the Products or
Referred Donor Products in an amount not less than $300,000 per occurrence for
product liability. If SeraCare's product liability or professional liability
insurance is claims-made (rather than occurrence) insurance, then, before this
Agreement expires, SeraCare shall purchase tail insurance covering claims that
arise after the Agreement expires.
8.3 CONFIDENTIALITY. The parties agree to maintain the
confidentiality of the contents of this Agreement. Neither party will
voluntarily disclose the contents of this
8
Agreement unless such disclosure is pre-approved in writing by the other party,
or such disclosure is required by law or governmental regulation.
8.4 ENTIRE AGREEMENT. This Agreement constitutes the entire
agreement between the parties with respect to the subject matter hereof and
shall supersede all prior written and oral and all contemporaneous oral
agreements and understandings with respect to the subject matter hereof.
8.5 DISPUTE RESOLUTION. Resolution of any and all disputes,
claims and causes of action of any nature whatsoever (collectively, "DISPUTES"),
arising from or relating to this Agreement, shall be exclusively governed by the
provisions of this Section 8.5.
(a) NEGOTIATION. The parties shall make a good faith attempt
to resolve any Dispute arising out of or relating to this Agreement through
informal negotiation between appropriate representatives from each of SeraCare
and Life Sciences. If at any time either party feels that such negotiations are
not leading to a resolution of the Dispute, such party may send a notice to the
other party describing the Dispute and requesting a meeting of the senior
executives from each party. Within ten (10) Business Days after such notice is
given, each party shall select appropriate senior executives of each party who
shall have the authority to resolve the matter and shall meet to attempt in good
faith to negotiate a resolution of the Dispute. During the course of
negotiations under this Section 8.5(a), all reasonable requests made by one
party to the other for information, including requests for copies of relevant
documents, will be honored. The specific format for such negotiations will be
left to the discretion of the designated negotiating senior executives but may
include the preparation of agreed upon statements of fact or written statements
of position furnished to the other party. In the event that any Dispute arising
out of or related to this Agreement is not settled by the parties within thirty
(30) days after the first meeting of the negotiating senior executives, either
party may submit the Dispute to arbitration pursuant to Section 8.5(b).
(b) ARBITRATION. All Disputes not resolved by good faith
negotiations among the parties pursuant to Section 8.5(a) within the prescribed
time period shall be submitted to, and determined by, arbitration. Such
arbitration shall proceed in accordance with the then-current rules for
arbitration established by the American Arbitration Association ("AAA"), unless
the parties hereto mutually agree otherwise, and pursuant to the following
procedures:
(i) The parties shall attempt in good faith to select from
the AAA panel one (1) arbitrator mutually acceptable to both parties
sitting in the state of New York. If the parties fail to agree upon an
arbitrator within fifteen (15) calendar days, an arbitrator shall be
selected by AAA in pursuant to the procedures set forth in AAA Rules.
The parties agree that for disputes involving $1 million or more
exclusive of claimed interest, arbitration fees and costs, the
procedures for "large complex commercial disputes" of the AAA shall
apply. In the event of a conflict, the provisions of this Agreement
will control.
(ii) Reasonable discovery shall be allowed in arbitration.
9
(iii) All proceedings before the arbitrator shall be held in
New York, New York. governing law shall be that of California.
(iv) The award rendered by the arbitrator shall be final and
binding, and judgment may be entered in accordance with applicable law
and in any court having jurisdiction thereof.
(v) The award rendered by the arbitrator shall include (A) a
provision that the prevailing party in such arbitration recover its
costs relating to the arbitration and reasonable attorneys' fees from
the other party, (B) the amount of such costs and fees, and (C) an
order that the losing party pay the fees and expenses of the
arbitrator.
(vi) The arbitrator shall by the agreement of the parties
expressly be prohibited from awarding punitive damages in connection
with any claim being resolved by arbitration hereunder.
(vii) All aspects of the arbitration shall be treated as
confidential. Neither the parties nor the arbitrator may disclose to
any third party the existence, content or results of the arbitration,
except as necessary to enforce the award in court or to comply with
legal or regulatory requirements.
8.6 GOVERNING LAW. This Agreement shall be construed in
accordance with and all Disputes hereunder shall be governed by the laws of the
State of California, excluding its conflict of law rules.
8.7 NOTICE. Any notice, demand, offer, request or other
communication required or permitted to be given by either party pursuant to the
terms of this Agreement shall be in writing and shall be deemed effectively
given the earlier of (i) when received, (ii) when delivered personally, (iii)
one (1) business day after being delivered by facsimile (with receipt of
appropriate confirmation), (iv) one (1) business day after being deposited with
an overnight courier service, or (v) four (4) days after being deposited in the
U.S. mail, First Class with postage prepaid, and addressed to the attention of
the party's Chief Executive Officer at the address of its principal executive
office or such other address as a party may request by notifying the other party
thereof in writing.
8.8 COUNTERPARTS. This Agreement, including other documents
referred to herein, may be executed in counterparts, each of which shall be
deemed to be an original but all of which shall constitute one and the same
agreement.
8.9 BINDING EFFECT; ASSIGNMENT. This Agreement shall inure to
the benefit of and be binding upon the parties hereto and their respective legal
representatives and successors, and nothing in this Agreement, express or
implied, is intended to confer upon any other Person any rights or remedies of
any nature whatsoever under or by reason of this Agreement. Except as herein
specifically provided to the contrary, neither party may assign this Agreement
or any rights or obligations hereunder, without the prior written consent of the
other party, and any such assignment shall be void; provided, however, either
party (or its permitted successive assignees or transferees hereunder) may
assign or transfer this Agreement as a whole without consent to an
10
entity that succeeds to all or substantially all of the business or assets of
such party to which this Agreement relates.
8.10 SEVERABILITY. The parties hereto have negotiated and
prepared the terms of this Agreement in good faith with the intent that each and
every one of the terms, covenants and conditions herein be binding upon and
inure to the benefit of the respective parties. Accordingly, if any one or more
of the terms, provisions, promises, covenants or conditions of this Agreement or
the application thereof to any person or circumstance shall be adjudged to any
extent illegal, invalid, unenforceable, void or voidable for any reason
whatsoever by a court of competent jurisdiction, then the parties agree to
negotiate immediately in good faith to amend the Agreement to preserve to the
maximum extent possible its original provisions. If the parties cannot agree on
an amended agreement within 60 days after the court's ruling, this Agreement
shall immediately terminate.
8.11 WAIVER OF BREACH. In order to enforce a waiver of any of
this Agreement's provisions, the enforcing party must have an express, written
waiver from the other party. The waiver by either party hereto of a breach or
violation of any provision of this Agreement shall not operate as, or be
construed to constitute, a waiver of any subsequent breach of the same or
another provision hereof.
8.12 AMENDMENT AND EXECUTION. This Agreement and amendments
hereto shall be in writing and executed in multiple copies via facsimile or
otherwise on behalf of SeraCare and Life Sciences by their respective duly
authorized officers and representatives. Each multiple copy shall be deemed an
original, but all multiple copies together shall constitute one and the same
instrument.
8.13 AUTHORITY. Each of the parties hereto represents to the
other that (a) it has the corporate or other requisite power and authority to
execute, deliver and perform this Agreement, (b) the execution, delivery and
performance of this Agreement by it have been duly authorized by all necessary
corporate or other actions, (c) it has duly and validly executed and delivered
this Agreement, and (d) this Agreement is a legal, valid and binding obligation,
enforceable against it in accordance with its terms subject to applicable
bankruptcy, insolvency, reorganization, moratorium or other similar laws
affecting creditors' rights generally and general equity principles.
8.14 Limitation of Liability.
(A) IN NO EVENT SHALL EITHER PARTY OR ITS SUBSIDIARIES BE
LIABLE TO THE OTHER PARTY OR ITS SUBSIDIARIES FOR ANY SPECIAL, CONSEQUENTIAL,
INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER CAUSED AND ON
ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) ARISING IN ANY WAY OUT OF THIS
AGREEMENT, WHETHER OR NOT SUCH OTHER PARTY HAS BEEN ADVISED OF THE POSSIBILITY
OF SUCH DAMAGES.
(B) IN NO EVENT SHALL SERACARE OR ITS SUBSIDIARIES BE LIABLE
TO LIFE SCIENCES OR ITS SUBSIDIARIES FOR ANY DIRECT, SPECIAL,
11
CONSEQUENTIAL, INDIRECT, INCIDENTAL OR PUNITIVE DAMAGES OR LOST PROFITS, HOWEVER
CAUSED AND ON ANY THEORY OF LIABILITY (INCLUDING NEGLIGENCE) IN THE EVENT THAT
THE PRODUCTS OR REFERRED DONOR PRODUCTS ARE MANUFACTURED FOR OTHER THAN
DIAGNOSTIC PURPOSES, HUMAN CONSUMPTION OR INJECTION INTO HUMANS.
12
IN WITNESS WHEREOF, each of the parties has caused this
Agreement to be executed on its behalf by its officers thereunto duly authorized
on the day and year first above written.
SERACARE, INC. SERACARE LIFE SCIENCES, INC.
By: /s/ Xxxxx Xxxxx By: /s/ Xxxxx Xxxxxxx
------------------------ ------------------------
Name: Xxxxx Xxxxx Name: Xxxxx Xxxxxxx
Title: President and CEO Title: Executive VP and CFO
[SIGNATURE PAGE TO SUPPLY AND SERVICES AGREEMENT]
13
LIST OF OMITTED EXHIBITS
The following Exhibits to the Supply and Services Agreement have been omitted
from this Exhibit and shall be furnished to the Commission upon request:
Exhibit Document
------- --------
D Centers
E Warrant Agreement
14
EXHIBIT A
PRODUCTS
------------------------------------- -----------------------------------
PRODUCT PRICE
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Reactive Units $50 per unit
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Orphan Plasma $35 per liter
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Male A/B Plasma $120 per liter
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Antibody Positive Plasma $120 per liter
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Antibody Negative Plasma $120 per liter
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
REFERRED DONOR SERVICES PRICE
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Referred Donor Plasma $200.00 per donor
------------------------------------- -----------------------------------
------------------------------------- -----------------------------------
Referred Donor Blood $35.00 per donor
------------------------------------- -----------------------------------
15
EXHIBIT B
MINIMUM SPECIFICATIONS
1. The Products supplied to Life Sciences shall be collected and tested in
accordance with FDA requirements and shall meet the minimum specifications
as per FDA source plasma guidelines.
2. The appearance of the Products shall be non-hemalized and non-lipemic.
3. SeraCare shall provide Life Sciences age, sex, race and data history of
donors as reasonably requested and permitted by law.
4. All Products shall be from Qualified Donors, as defined by the American
Blood Resources Association (ABRA) Quality Plasma Program.
5. SeraCare shall follow all SeraCare established Standard Operating
Procedures in effect as of the date hereof, as may be amended from time to
time in accordance with Section 3.1 of the Supply and Services Agreement.
16
EXHIBIT C
REFERRED DONOR MINIMUM SPECIFICATIONS
1. The Products supplied to Life Sciences shall be collected and tested in
accordance with FDA requirements and shall meet the minimum specifications
as per FDA source plasma guidelines.
2. The appearance of the Products shall be non-hemalized and non-lipemic.
3. SeraCare shall provide Life Sciences age, sex, race and data history of
donors as reasonably requested and permitted by law.
4. SeraCare shall follow all Life Sciences established Standard Operating
Procedures, which have been delivered to SeraCare as of the date hereof,
and as may be amended from time in the sole discretion of Life Sciences.
17
